Answers are grounded in this paper and cite their sources.
BACKGROUND: Recently, measurement of very low concentrations of C-reactive protein (CRP) has gained popularity as a potential new means for predicting the risk of future cardiac complications. In this study, we demonstrate the feasibility of a kinetic, one-step microparticle assay for quantitative determination of extremely low and high CRP concentrations in the limited timeframe typical for point-of-care testing. METHODS: A noncompetitive, kinetic CRP immunoassay was developed that uses individual, porous microparticles as the solid phase. The microparticles were covalently coated with a monoclonal capture antibody, and the monoclonal detection antibody was labeled with europium. The one-step binding reaction was stopped by washing after 2 min of incubation, and the fluorescence signal of individual particles was measured. RESULTS: The analytical detection limit (mean of zero calibrator + 3 SD) was 0.00016 mg/L CRP. Clinical samples were diluted 400-fold before assay to cover the CRP concentration range of 0.064-1200 mg/L. The assay correlated well with the Dade Behring N High Sensitivity CRP assay (for 0-10 mg/L, r = 0.969, S(y/x) = 0.68, n = 54; for 0-350 mg/L, r = 0.969, S(y/x) = 11.7, n = 100). The within- and between-run CVs based on calculated concentrations were, respectively, 9-16% and 14% at 0.11 mg/L, 4.5-12% and 8.2% at 4.2 mg/L, and 3.5-6.3% and 4.4% at 105 mg/L, with a CV <15% at 0.2 mg/L and above. CONCLUSIONS: Use of the kinetic microparticle approach combined with time-resolved fluorometry allows ultrasensitive quantification of CRP in whole blood in 2 min with a linear assay range spanning more than four orders of magnitude.
No takes yet. Share an insight, caveat, or question.
Tarkkinen et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: